A Multicentric, International, Randomized, Double-Blind, Placebo-Controlled, Phase II/III (MYODA-INT) Study to Evaluate the Safety and Efficacy of a Sarconeos Dose in Ambulant Boys with Duchenne Myopathy

Next Previous
Trial Profile

A Multicentric, International, Randomized, Double-Blind, Placebo-Controlled, Phase II/III (MYODA-INT) Study to Evaluate the Safety and Efficacy of a Sarconeos Dose in Ambulant Boys with Duchenne Myopathy

Planning
Phase of Trial: Phase II/III

Latest Information Update: 23 Mar 2018

At a glance

  • Drugs Sarconeos (Primary)
  • Indications Duchenne muscular dystrophy
  • Focus Registrational; Therapeutic Use
  • Acronyms MYODA-INT
  • Sponsors Biophytis

    • Most Recent Events

    • 23 Mar 2018 New trial record
    • 20 Mar 2018 According to a Biophytis media release, this study is expected to start in 2019 and the results of this study should allow to file for a conditional marketing authorization.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top